Material and Energy Balances in the Process of Anti-Bacterial Drugs from Erythromycin
DOI:
https://doi.org/10.37628/jcep.v7i2.1140Abstract
Erythromycin is a crucial material for production of active pharmaceutical ingredient with several different applications to treat diseases. Demand for erythromycin derivatives has been accumulated within the last twenty years and drastically in last 2 years as a key raw material for COVID-19. Clarithromycin is one amongst the derivatives of erythromycin that has higher anti-bacterial properties. This paper involves manufacture of Clarithromycin, an anti-bacterial drug, from Erythromycin. Selective methylation of erythromycin is chosen as best route for production of Clarithromycin over different routes because of high purity of 97 of product yield. Method flowsheet for the complete producing unit is developed. The report is finished supported 100TPA of Clarithromycin with material and energy balances followed by instrumentation design is given. Within the design method, batch reactor is chosen as most of the pharmaceutical processes involve batch operations. Materials for instrumentation are designated looking on method operations and controllers required are evaluated. Instrumentation and control of the distillation column is given with all method parameters. Safety aspects for handling materials also are given.
References
Zuckerman JM. The newer macrolides: azithromycin and clarithromycin. Infect Dis Clin North Am. 2000 Jun;14(2):449-62, x. doi: 10.1016/s0891-5520(05)70257-9. PMID: 10829265.
“Method for selective methylation of erythromycin A derivatives” by Shigeo Morimoto, Takashi Adachi, Toshifumi Asaka, Masato Kashimura, Yoshiaki Watanabe and Kaoru Sota, 1985, https://patents.google.com/patent/CA1225637A
Jih-Hua Liu, David A. Riley and Steven G. Spanton, Crystal form I of clarithromycin, U.S. Patent Number: 5,858,986, Assignee: Abbott Laboratories, Abbott Park, Ill, 1997.
Shigeo Morimoto, Yoko Takahashi, Yoshiaki Watanabe, Sadafumi Omura, Chemical modification of Erythromycin ,The Journal Of Antibiotics Volume 46 (CHEMICAL MODIFICATION OF ERYTHROMYCINS (jst.go.jp)), 1993, https://doi.org/10.7164/antibiotics.37.187.
Morimoto S, Takahashi Y, Watanabe Y, Omura S. Chemical modification of erythromycins. I. Synthesis and antibacterial activity of 6-O-methylerythromycins A. J Antibiot (Tokyo). 1984 Feb;37(2):187-9. doi: 10.7164/antibiotics.37.187. PMID: 6706855.
Watanabe Y, Morimoto S, Adachi T, Kashimura M, Asaka T. Chemical modification of erythromycins. IX. Selective methylation at the C-6 hydroxyl group of erythromycin A oxime derivatives and preparation of clarithromycin. J Antibiot (Tokyo). 1993 Apr;46(4):647-60. doi: 10.7164/antibiotics.46.647. PMID: 8501007.
Faubl,H. & R.G.Stein (Abbott), Erythromycin A silylated compounds and method of use, U.S. 4,640,910, Feb. 3, 1987, https://doi.org/10.7164/antibiotics.46.1163.
Watanbe, S. Morimoto, H.Goi, M.Mitsu-Kuchi, T. Adachi, J.Nakagami, T.Asaka, T.Eguchi & K.Sota (Taisho), Method for selective methylation of erythromycin A derivatives. U.S.4,672,109, June9,1987,DOI: 10.1248/yakushi1947.112.9_593.
Morimoto, Y.Takahashi, Y.Watanbe & S. Omura, Chemical modification of erythromycins. I. Synthesis and antibacterial activity of 6-O-methylerythromycins A. J. Antibiotics 37: 187-189, 1984. DOI https://doi.org/10.7164/antibiotics.43.295.
D.Q. Kern, Process Heat Transfer, 1st edition, Mc Graw Hill Company, 1965.
James R. Cooper, Process Engineering Economic, Marcel Delkker Inc, New York, 2003
